Avadel Pharmaceuticals PLC (STU:AWK)
€ 10 0.15 (1.52%) Market Cap: 949.15 Mil Enterprise Value: 888.38 Mil PE Ratio: 0 PB Ratio: 13.69 GF Score: 42/100

Avadel Pharmaceuticals PLC at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 05:00PM GMT
Release Date Price: €13.4 (-1.47%)
Andrew Tsai
Jefferies & Company, Inc. - Analyst

With us today and it's my pleasure to have the Avadel team with me. I've got to the right of me Greg Divis, CEO; and to the right of him Richard Kim, CCO. Welcome both of you. Great. And so team, maybe briefly for a couple minutes for those in the audience who might not be as familiar with the Avadel story can you give us a background about your company. Congratulations, by the way, on the approval, but I'll let you take it away from there.

Greg Divis
Avadel Pharmaceuticals plc - CEO

Yeah I won't belabor almost 40 years of history of the company. I think most importantly over the last number of years we've been exclusively focused on a rare sleep medicine in particular narcolepsy with our lead program LUMRYZ, which as of May 1, was approved by the FDA for patients with narcolepsy suffering from excessive daytime sleepiness and or cataplexy.

Along with that FDA approval was LUMRYZ was granted full orphan drug exclusivity and was determined to be clinically superior to the first-generation twice

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot